19 Jul Excellos
Robert Tressler, Ph.D., Chief Scientific Officer
Oct. 7 | 10:15am | FLW Ballroom G
San Diego, CA
(Private)
Excellos is a CDMO specializing in servicing the adaptive immunotherapies space on behalf of our Biopharma clients. Our services span source material supply, characterization, cell manufacturing and gene editing for CAR, T, NK, TIL and HSPC-based immunotherapies for the treatment of oncology, autoimmune and regenerative medicine indications. We have developed a novel E360 donor and cell assessment platform that is a unique approach to identify preferred allogeneic donors to serve sources of high quality starting materials for allogeneic adaptive immunotherapy-based approaches. The E360 assessment tool also can be used to monitor the quality of manufacturing intermediates, support QbD process development activities and characterize final product to assure an optimal final product for the patient. We also offer custom testing and characterization for potency, identity and purity as well as cell expansion services with a focus on supplying more consistent optimal products.
